We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
Read MoreHide Full Article
ImmunoGen, Inc. announced that the FDA has granted Fast Track designation to its lead candidate, mirvetuximab soravtansine, a first-in-class antibody drug conjugate targeting folate-receptor (“FR”) alpha. The designation is for the development of the candidate in platinum-resistant ovarian cancer patients with medium to high FR alpha positive.
The patients must have received at least one but no more than three prior systemic treatment regimens and single-agent chemotherapy is the appropriate next line of therapy.
With the FDA granting fast track designation, the candidate’s development and review are expected to accelerate. The designation is granted to candidates, which treat serious and unmet medical conditions. With this designation, a candidate is expected to be granted a priority review once it files a new drug application.
ImmunoGen’s shares were up almost 5.8% including after-hours trading on Jun 18. Shares of the company have rallied 61.2% compared with the industry’s rise of 4.6%, so far this year.
The company is evaluating mirvetuximab soravtansine in a phase III study — FORWARD I — for the treatment of platinum-resistant ovarian cancer expressing medium or high levels of FR alpha against a single-agent chemotherapy. The primary endpoint of the study is progression free survival. Enrollment in the study was completed ahead of schedule in April and top-line data is expected in the first half of 2019.
A phase Ib/II FORWARD II study is evaluating the candidate in combination with Roche’s (RHHBY - Free Report) Avastin or Merck’s (MRK - Free Report) anti PD-L1 therapy, Keytruda, in platinum-sensitive ovarian cancer expressing FR alpha. The study is also evaluating a triplet combination – mirvetuximab plus carboplatin and Avastin.
With no approved product in its portfolio, the progress of its lead candidate is driving the stock. Investors should remain focused on further updates on mirvetuximab.
Aeglea’s loss estimates narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the last 60 days. The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. Its share price has increased 101.3% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
ImmunoGen, Inc. announced that the FDA has granted Fast Track designation to its lead candidate, mirvetuximab soravtansine, a first-in-class antibody drug conjugate targeting folate-receptor (“FR”) alpha. The designation is for the development of the candidate in platinum-resistant ovarian cancer patients with medium to high FR alpha positive.
The patients must have received at least one but no more than three prior systemic treatment regimens and single-agent chemotherapy is the appropriate next line of therapy.
With the FDA granting fast track designation, the candidate’s development and review are expected to accelerate. The designation is granted to candidates, which treat serious and unmet medical conditions. With this designation, a candidate is expected to be granted a priority review once it files a new drug application.
ImmunoGen’s shares were up almost 5.8% including after-hours trading on Jun 18. Shares of the company have rallied 61.2% compared with the industry’s rise of 4.6%, so far this year.
The company is evaluating mirvetuximab soravtansine in a phase III study — FORWARD I — for the treatment of platinum-resistant ovarian cancer expressing medium or high levels of FR alpha against a single-agent chemotherapy. The primary endpoint of the study is progression free survival. Enrollment in the study was completed ahead of schedule in April and top-line data is expected in the first half of 2019.
A phase Ib/II FORWARD II study is evaluating the candidate in combination with Roche’s (RHHBY - Free Report) Avastin or Merck’s (MRK - Free Report) anti PD-L1 therapy, Keytruda, in platinum-sensitive ovarian cancer expressing FR alpha. The study is also evaluating a triplet combination – mirvetuximab plus carboplatin and Avastin.
With no approved product in its portfolio, the progress of its lead candidate is driving the stock. Investors should remain focused on further updates on mirvetuximab.
ImmunoGen, Inc. Price
ImmunoGen, Inc. Price | ImmunoGen, Inc. Quote
Zacks Rank & Stocks to Consider
ImmunoGen currently carries a Zacks Rank #3 (Hold).
Aeglea BioTherapeutics, Inc. is a better-ranked stock in the pharma sector carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aeglea’s loss estimates narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the last 60 days. The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. Its share price has increased 101.3% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>